Nestlé Health said that employees of Prometheus are becoming employees of Precision IBD, with the exception of those working in its point-of-care diagnostic business.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
Based in Austria, EuroLyser develops point-of-care testing devices and kits. ArchiMed also acquired EuroLab, EuroLyser's main distributor.
The test measures levels of seven auto-antibodies to tumor-associated antigens, and is designed to detect all forms of lung cancer at any stage.
Transplant Genomics offers a test that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection.
As part of the deal, Alpharetta, Georgia-based Ascenda acquired Provista's Videssa Breast test, a blood-based proteomic test for aiding assessment of indeterminate mammograms.
The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.
The resulting company will retain the Lumos name and focus on the international launch of RPS' FebriDx test for febrile acute respiratory infections.
The partners believe their technology could have advantages over others used in early-stage cancer detection, such as next-generation sequencing.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.